Hepatitis C virus eradication on glycemic control and insulin resistance

Carvalhal, Manuela Maria de Lima; Kikuchi, Jeane Lorena Dias; Gomes, Daniela Lopes; Quaresma, Juarez Antônio Simões

doi:10.1590/1806-9282.20210752

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 2015, the Brazilian public health system has provided DAA free of charge, with more than 150,000 individuals with HCV treated to date ( 18 ). Despite high SVR rates and excellent tolerability with DAAs, few Brazilian studies have assessed the impact of SVR on glucose metabolism ( 19 , 20 ). Thus, the aim of the present study was to compare glycated hemoglobin (HbA1c) levels obtained before and after SVR and investigate potential baseline characteristics associated with this outcome in a cohort of individuals with chronic HCV infection who achieved SVR with DAA therapy at a tertiary referral center in the Southern Region of Brazil.…”

Section: Introductionmentioning

confidence: 99%

Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals

Benetti,

Araújo,

de Maman

et al. 2024

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after direct-acting antivirals (DAA) therapy. Materials and methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of HbA1c were measured up to 24 weeks before DAA therapy and 12 weeks after SVR. Exclusion criteria were decompensated cirrhosis, HIV and/or hepatitis B virus, liver disease of other etiologies, and/or modification of prediabetes/type 2 diabetes mellitus (PDM/T2DM) management. The primary outcome was a comparison of HbA1c levels before and after SVR. Secondary outcomes were the baseline variables associated with improved glycemic control. Results: The study included 207 patients with a mean age of 60.6±10.7 years, of whom 51.7% were women, 56% had cirrhosis, 37.7% had HCV genotype 3, and 54.5% had baseline T2DM or PDM. The median HbA1c level reduced significantly after SVR (5.5%, interquartile range [IQR] 4.9%-6.3%) compared with baseline (5.7%, IQR 5.3%-6.7%; p = 0.01). The baseline characteristics associated with improved HbA1c after SVR were cirrhosis, genotype 3, and age ≤ 60 years. Conclusion: Among patients with CHC, SVR after DAA was associated with HbA1c reduction, particularly in those with cirrhosis, genotype 3, and age ≤ 60 years.

show abstract

Section: Introductionmentioning

confidence: 99%